Seeking Alpha

A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of...

A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of Propofol, marking the third verdict against Baxter International (BAX -1.2%) and Teva Pharmaceuticals (TEVA +0.7%) over an outbreak in the state tied to use of the drug. An attorney for Teva passes off blame to doctors: "It’s not a vial problem... it’s a practice problem."
Comments (1)
  • coonhound
    , contributor
    Comment (1) | Send Message
     
    The story is incomplete, the jury is awarding 100's of millions of dollars to patients. I was an anesthesiologist for 30 years and Propofol was never in reusable vials. The jury had a chance to stick it to big business and they did. They should have stuck it to the anesthetist who was unaware of the germ theory of disease.
    11 Oct 2011, 02:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector